Beckman Coulter Dips into AI with New Acquisition

With the acquisition, StoCastic's TriageGo will be a cornerstone of Beckman Coulter's Clinical Decision Support portfolio.

MDDI Staff

October 11, 2022

1 Min Read
Image courtesy of Michael Vi / Alamy Stock Photo

Beckman Coulter Diagnostics latest acquisition has it swimming in the artificial intelligence side of the medtech pool.

The Brea, CA-based company said earlier today, that it has acquired StoCastic, an AI company that provides evidence-based decision support for hospital emergency departments.

StoCastic's TriageGo decision support tool seamlessly integrates Electronic Health Record systems and routine emergency department workflow.

The purpose of emergency department triage is to differentiate patients' criticality, yet 60% to 70% of all patients in the U.S. are triaged to an ambiguous Emergency Severity Index Level 3, meaning the projected course of care is uncertain.  TriageGo has been shown to reduce decision making times in the emergency department, including decreasing door-to-clinical decision time by 20 to 30 minutes, door-to-ICU times by 40 to 80 minutes and door-to-ED departure for those having emergency surgery by 30 to 60 minutes.

"We are thrilled to be joining Beckman Coulter Diagnostics," said Eric Hamrock, Senior Director, CDS Service, Beckman Coulter Diagnostics and former CEO, StoCastic LLC.  "Beckman Coulter will bring world-class market understanding and customer experience leadership, in addition to their commitment to supporting and building upon StoCastic's customers' success, making this a perfect fit for our organization."

Sign up for the QMED & MD+DI Daily newsletter.

You May Also Like